May 5, 2022

Thursday, May 5, 2022

by Gist Healthcare

https://assets.pippa.io/shows/622b8f5080a3a00013890f23/show-cover.png

Listen Time: 5:39

The FDA says there’s “no evidence” that doubling an individual’s dose of Paxlovid will reduce the return of COVID symptoms. Mental health telemedicine company Cerebral stops prescribing Adderall to new patients as the company faces increasing scrutiny for its marketing and prescribing practices. And a Health Affairs study finds several physicians in insurers’ Medicaid networks aren’t seeing patients.


See acast.com/privacy for privacy and opt-out information.